IL288174B1 - Pyrrolidine compounds - Google Patents
Pyrrolidine compoundsInfo
- Publication number
- IL288174B1 IL288174B1 IL288174A IL28817421A IL288174B1 IL 288174 B1 IL288174 B1 IL 288174B1 IL 288174 A IL288174 A IL 288174A IL 28817421 A IL28817421 A IL 28817421A IL 288174 B1 IL288174 B1 IL 288174B1
- Authority
- IL
- Israel
- Prior art keywords
- tert
- oxo
- methyl
- mmol
- butoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382477 | 2019-06-07 | ||
| PCT/US2020/035825 WO2020247429A1 (en) | 2019-06-07 | 2020-06-03 | Pyrrolidine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL288174A IL288174A (en) | 2022-01-01 |
| IL288174B1 true IL288174B1 (en) | 2025-08-01 |
Family
ID=66821161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288174A IL288174B1 (en) | 2019-06-07 | 2020-06-03 | Pyrrolidine compounds |
| IL321703A IL321703A (en) | 2019-06-07 | 2020-06-03 | Pyrrolidine compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321703A IL321703A (en) | 2019-06-07 | 2020-06-03 | Pyrrolidine compounds |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11286249B2 (enExample) |
| EP (1) | EP3980409A1 (enExample) |
| JP (4) | JP6940717B2 (enExample) |
| KR (3) | KR102629923B1 (enExample) |
| CN (1) | CN114008021B (enExample) |
| AU (1) | AU2020287599B2 (enExample) |
| BR (1) | BR112021023347A2 (enExample) |
| CA (1) | CA3140869A1 (enExample) |
| CL (1) | CL2021003202A1 (enExample) |
| CO (1) | CO2021016295A2 (enExample) |
| CR (1) | CR20210602A (enExample) |
| DO (1) | DOP2021000254A (enExample) |
| EA (1) | EA202193007A1 (enExample) |
| EC (1) | ECSP21088515A (enExample) |
| IL (2) | IL288174B1 (enExample) |
| JO (1) | JOP20210319A1 (enExample) |
| MA (1) | MA56115A (enExample) |
| MX (2) | MX2021014913A (enExample) |
| MY (1) | MY200810A (enExample) |
| PE (1) | PE20220134A1 (enExample) |
| PH (1) | PH12021553062A1 (enExample) |
| SA (1) | SA521431048B1 (enExample) |
| SG (1) | SG11202113244UA (enExample) |
| UA (1) | UA128540C2 (enExample) |
| WO (1) | WO2020247429A1 (enExample) |
| ZA (1) | ZA202109251B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240091010A (ko) | 2021-11-03 | 2024-06-21 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | 치환된 페닐프로피온산 유도체 및 이의 용도 |
| WO2023146785A1 (en) | 2022-01-26 | 2023-08-03 | Eli Lilly And Company | Pyrrolidine compounds |
| WO2024199070A1 (zh) * | 2023-03-24 | 2024-10-03 | 上海京新生物医药有限公司 | 一种环状胺衍生物及其组合物与应用 |
| WO2024217537A1 (zh) * | 2023-04-21 | 2024-10-24 | 深圳信立泰药业股份有限公司 | 一种叔胺类化合物及其制备方法和医药用途 |
| WO2024230805A1 (zh) * | 2023-05-11 | 2024-11-14 | 江苏恒瑞医药股份有限公司 | 一种脂蛋白化合物晶型及其制备方法 |
| WO2024240056A1 (zh) * | 2023-05-19 | 2024-11-28 | 深圳信立泰药业股份有限公司 | 一种磺酰胺类化合物及其制备方法和医药用途 |
| WO2025006661A1 (en) | 2023-06-30 | 2025-01-02 | Eli Lilly And Company | Therapeutic uses and doses of lp(a) disrupter compounds |
| WO2025024218A1 (en) | 2023-07-21 | 2025-01-30 | Eli Lilly And Company | PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY |
| WO2025024216A1 (en) | 2023-07-21 | 2025-01-30 | Eli Lilly And Company | PYRROLIDINE COMPOUNDS Lp(a) LOWERING ACTIVITY |
| WO2025024210A1 (en) | 2023-07-21 | 2025-01-30 | Eli Lilly And Company | Piperidine, morpholine and tetrahydro-pyridazine compounds with lp(a) lowering activity |
| WO2025024211A1 (en) | 2023-07-21 | 2025-01-30 | Eli Lilly And Company | Piperidine Compounds with Lp(a) Lowering Activity |
| WO2025103442A1 (zh) * | 2023-11-17 | 2025-05-22 | 上海翊石医药科技有限公司 | 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途 |
| WO2025108255A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海齐鲁制药研究中心有限公司 | 一种多环类衍生物、其制备方法和应用 |
| WO2025237188A1 (zh) * | 2024-05-14 | 2025-11-20 | 石家庄以岭药业股份有限公司 | 一种LP(a)抑制剂化合物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452521A1 (en) * | 2001-08-17 | 2004-09-01 | Eisai Co., Ltd. | Cyclic compound and ppar agonist |
| WO2005068412A1 (en) * | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2685325B1 (fr) * | 1991-12-20 | 1994-02-04 | Adir Cie | Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AU2003300438A1 (en) * | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| JP2010534701A (ja) | 2007-07-27 | 2010-11-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｔａａｒリガンドとしての２−アゼチジンメタンアミン及び２−ピロリジンメタンアミン |
| WO2017133591A1 (zh) | 2016-02-03 | 2017-08-10 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| CN112321475B (zh) | 2020-11-13 | 2022-06-10 | 四川大学 | 一种γ-氨基酸类似物及其合成方法 |
-
2020
- 2020-06-03 MX MX2021014913A patent/MX2021014913A/es unknown
- 2020-06-03 CA CA3140869A patent/CA3140869A1/en active Pending
- 2020-06-03 IL IL288174A patent/IL288174B1/en unknown
- 2020-06-03 KR KR1020227043106A patent/KR102629923B1/ko active Active
- 2020-06-03 PE PE2021002037A patent/PE20220134A1/es unknown
- 2020-06-03 MA MA056115A patent/MA56115A/fr unknown
- 2020-06-03 CR CR20210602A patent/CR20210602A/es unknown
- 2020-06-03 JO JOP/2021/0319A patent/JOP20210319A1/ar unknown
- 2020-06-03 AU AU2020287599A patent/AU2020287599B2/en active Active
- 2020-06-03 MY MYPI2021007256A patent/MY200810A/en unknown
- 2020-06-03 US US17/056,144 patent/US11286249B2/en active Active
- 2020-06-03 CN CN202080041924.XA patent/CN114008021B/zh active Active
- 2020-06-03 JP JP2021505713A patent/JP6940717B2/ja active Active
- 2020-06-03 BR BR112021023347A patent/BR112021023347A2/pt unknown
- 2020-06-03 WO PCT/US2020/035825 patent/WO2020247429A1/en not_active Ceased
- 2020-06-03 EA EA202193007A patent/EA202193007A1/ru unknown
- 2020-06-03 UA UAA202106553A patent/UA128540C2/uk unknown
- 2020-06-03 SG SG11202113244UA patent/SG11202113244UA/en unknown
- 2020-06-03 EP EP20747210.1A patent/EP3980409A1/en active Pending
- 2020-06-03 IL IL321703A patent/IL321703A/en unknown
- 2020-06-03 KR KR1020217040065A patent/KR102477481B1/ko active Active
- 2020-06-03 KR KR1020247002433A patent/KR102720992B1/ko active Active
- 2020-06-03 PH PH1/2021/553062A patent/PH12021553062A1/en unknown
-
2021
- 2021-09-02 JP JP2021143227A patent/JP7508422B2/ja active Active
- 2021-11-18 ZA ZA2021/09251A patent/ZA202109251B/en unknown
- 2021-11-30 CO CONC2021/0016295A patent/CO2021016295A2/es unknown
- 2021-12-01 CL CL2021003202A patent/CL2021003202A1/es unknown
- 2021-12-03 MX MX2025001789A patent/MX2025001789A/es unknown
- 2021-12-07 EC ECSENADI202188515A patent/ECSP21088515A/es unknown
- 2021-12-07 DO DO2021000254A patent/DOP2021000254A/es unknown
- 2021-12-07 SA SA521431048A patent/SA521431048B1/ar unknown
-
2022
- 2022-02-15 US US17/671,806 patent/US12441714B2/en active Active
-
2024
- 2024-06-18 JP JP2024098153A patent/JP7658014B2/ja active Active
-
2025
- 2025-03-26 JP JP2025052039A patent/JP2025098178A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452521A1 (en) * | 2001-08-17 | 2004-09-01 | Eisai Co., Ltd. | Cyclic compound and ppar agonist |
| WO2005068412A1 (en) * | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
Non-Patent Citations (2)
| Title |
|---|
| ESPERION THERAPEUTICS INC [US], WO 2005068410 A1, 28 July 2005 (2005-07-28) * |
| JIN JING YI ET AL,, SYNTHESIS AND STRUCTURE DETERMINATION OF (2 S , 2' S )-3-PHENYL-2-(PYRROLIDIN-2'-YL)- PROPIONIC ACID, 18 August 2006 (2006-08-18) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020287599B2 (en) | Pyrrolidine compounds | |
| KR102219441B1 (ko) | 메틸 변형 효소 조절제, 이의 조성물 및 용도 | |
| US9586947B2 (en) | Imidazoline derivatives, preparation methods thereof, and their applications in medicine | |
| RU2618628C1 (ru) | Производные N-пиперидин-3-илбензамида для лечения сердечно-сосудистых заболеваний | |
| CA2749317A1 (en) | Fluorine containing compounds and methods of use thereof | |
| WO2010146488A1 (en) | Bicyclic and tricyclic compounds as kat ii inhibitors | |
| JP5355551B2 (ja) | キノロン化合物及び医薬組成物 | |
| JP2009536609A (ja) | Ｃｅｔｐ阻害剤としてのベンジルアミン誘導体 | |
| JP5769504B2 (ja) | 医薬 | |
| EA045074B1 (ru) | Соединения пирролидина | |
| JP7716980B2 (ja) | エストロゲン受容体拮抗剤 | |
| WO2025024211A1 (en) | Piperidine Compounds with Lp(a) Lowering Activity | |
| CN113801135B (zh) | 噻吩并吡唑类化合物，包含其的药物组合物及其用途 | |
| WO2025024210A1 (en) | Piperidine, morpholine and tetrahydro-pyridazine compounds with lp(a) lowering activity | |
| WO2025024216A1 (en) | PYRROLIDINE COMPOUNDS Lp(a) LOWERING ACTIVITY | |
| WO2025024218A1 (en) | PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY |